الفهرس 
Pathobiology of Hemorrhagic ShockOnly 14 pages are availabe for public view
 |  | from | 96 |  |  |
| | | from | 96 | | |
Abstract
The current study aimed to assess the effectiveness of high fixed transfusion ratios (1:1:1) of plasma, platelets, and RBCs in patients with critical non-traumatic and traumatic hemorrhage, and to evaluate the relationship between transfusion ratios and clinical outcomes. The study was conducted on patients admitted with massive critical bleeding in the intensive care unit (ICU) of Benha University hospitals from May to December 2022.
The results of the study showed that there were no significant differences in age, gender, or cause of hemorrhagic shock between patients who survived and those who did not. However, non-survivors had a significantly higher number of RBCs transfused compared to survivors. The shock index was also found to be significantly higher in non-survivors.
In terms of transfusion ratios, the study found no significant differences in all given blood products, including RBCs, FFP, platelets, and cryoprecipitate, between survivors and non-survivors.
The SI is a simple bedside tool that can be used early to predict the need of blood transfusion, particularly for those may benefit from early call for MTP and intervention. It also has correlation with other physiological, anatomical, and laboratory predictors. However, its cutoff values for risk stratification and prognostication need further evaluation in trauma patients.
In conclusion, the high fixed transfusion ratio of 1:1:1 for plasma, platelets, and RBCs may not have a significant impact on the clinical outcomes of patients with critical non-traumatic and traumatic hemorrhage. However, the implementation of a massive transfusion protocol may lead to better outcomes in terms of 30-day mortality. Further interventional studies are needed to confirm these findings.